Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease

NCT01124643 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01124643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01124643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
April 13, 2010
Completion date
July 8, 2013
Enrollment
35 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease